VRAX Stock Risk & Deep Value Analysis
Virax Biolabs Group Ltd
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About VRAX Stock
We analyzed Virax Biolabs Group Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VRAX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
VRAX Risk Analysis & Red Flags
What Could Go Wrong
The 300-participant validation study for ViraxImmune™ could fail to demonstrate statistical significance or robust performance (88% specificity, 92% PPV in pilot), invalidating the product and likely rendering the company's current ~$4.26M implied market value and $6.4M cash position insufficient to sustain operations without a viable core product.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Lack of verifiable revenue generation since inception, indicating an unproven commercial model.
- ⚠
History of significant share dilution (as noted in previous analysis) to fund operations, without proportional value creation.
- ⚠
TipRanks 'Sell' technical consensus despite an average price target of $3.00, which suggests highly speculative or outdated analyst coverage.
- ⚠
Current market capitalization listed as $0.00B in initial prompt header (though implied ~$4.26M by institutional ownership), highlighting extreme micro-cap status and potential data ambiguity/liquidity issues.
- ⚠
No identified Form 4 insider buying in the last 90 days, despite positive pilot data.
Upcoming Risk Events
- 📅
Failure of the 300-participant validation study for ViraxImmune™ to replicate positive pilot data or meet primary endpoints (est. Q3/Q4 2026) – would severely undermine product viability.
- 📅
Inability to secure sufficient commercialization partners or additional funding, leading to rapid cash depletion and potential bankruptcy given lack of revenue (est. within 12-18 months).
When to Reconsider
- 🚪
Exit if Virax Biolabs announces negative or inconclusive results from the 300-participant ViraxImmune™ validation study.
- 🚪
Sell if the company's cash and equivalents fall below $3.0 million without a confirmed new funding round or partnership to extend its operational runway.
Unlock VRAX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Virax Biolabs Group Ltd (VRAX) Do?
Market Cap
$4.23M
Sector
Healthcare
Industry
Biotechnology
Employees
19
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Visit Virax Biolabs Group Ltd WebsiteInvestment Thesis
If Virax Biolabs successfully completes its 300-participant validation study for ViraxImmune™ for Long COVID/PAIS with strong positive results and subsequently secures a significant commercialization partnership or non-dilutive funding within the next 12-18 months, then its current implied market cap of ~$4.26M could re-rate significantly, potentially reaching $50-100M (10-20x current valuation) as the market begins to value its validated diagnostic pipeline. This is bullish because the current price reflects only highly speculative, early-stage R&D with minimal market validation, and a successful validation and partnership would de-risk a major portion of its existential threat.
Is VRAX Stock Undervalued?
Unlock the full AI analysis for VRAX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
VRAX Price Targets & Strategy
12-Month Target
$0.50
Bull Case
$1.00
Bear Case
$0.05
Valuation Basis
Speculative re-rating to ~$10M-$20M market cap (approx. 2.3x-4.7x current implied valuation) based on successful ViraxImmune™ validation and commercialization pathway clarity within 12 months.
Entry Strategy
Dollar-cost average at current levels (below $0.25) due to extreme volatility and speculative nature. Accumulate on any dips to $0.15-$0.20 if accompanied by no new negative news.
Exit Strategy
Take 50% profit at $0.75 upon significant positive catalyst (e.g., major partnership). Implement a strict stop-loss at $0.10 to manage extreme downside risk.
Portfolio Allocation
0.5% for aggressive risk tolerance only, as this is a highly speculative 'moonshot' position.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is VRAX Financially Healthy?
Valuation
P/E Ratio
1321.80
EV/EBITDA
-0.42
PEG Ratio
0.01
Price/Book
0.62
Profitability
Gross Margin
-1515.05%
Operating Margin
-196303.34%
Net Margin
-188748.83%
Return on Equity
-102.54%
Revenue Growth
-96.48%
EPS
$-1.25
Balance Sheet
Current Ratio
7.27
Quick Ratio
6.33
Debt/Equity
0.07
Other
Beta (Volatility)
1.22
Does VRAX Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Not applicable; too early in development to establish or assess a trend.
Moat Sources
1 Identified
The potential moat relies entirely on successful and unique scientific development, robust patent protection, and rapid commercialization. If competing technologies emerge or regulatory hurdles are too high, any nascent moat would quickly erode.
Moat Erosion Risks
- •Failure to secure robust patent protection for ViraxImmune™ or its underlying technology.
- •Emergence of superior or more cost-effective diagnostic technologies from larger, well-funded competitors.
- •Inability to achieve widespread adoption or regulatory approval, limiting market penetration and brand power.
VRAX Competitive Moat Analysis
Sign up to see competitive advantages
VRAX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Speculative Bullish. Retail interest may be high due to low share price and potential 'moonshot' narratives, but also a strong awareness of the extreme risks.
Institutional Sentiment
Negative, indicated by TipRanks 'Sell' technical consensus (4 bullish / 0 neutral / 9 bearish technical signals). Armistice Capital's 4.99% stake is a passive position and does not signal strong conviction buying.
Insider Activity (Form 4)
No Form 4 insider transactions (buys or sells) were identified in the last 90 days. The only relevant filing is Armistice Capital's Schedule 13G/A reporting a 4.99% passive institutional ownership on 05/15/2026.
Options Flow
Normal options activity; no specific unusual options flow or extreme put/call ratio skew was identified in the provided research.
Earnings Intelligence
Next Earnings
Not verifiable from provided sources; TipRanks states next EPS estimate is 'not yet available'.
Surprise Probability
N/A - The company has no consistent revenue or earnings history, making surprise probabilities irrelevant.
Historical Earnings Pattern
Not applicable due to lack of consistent reported earnings and revenue generation. Stock price reactions are likely driven by product development and financing news rather than traditional earnings reports.
Key Metrics to Watch
Competitive Position
Top Competitor
No direct best-in-class competitor can be identified from the provided research, as the Long COVID diagnostic market is still nascent and highly fragmented. Larger diagnostic companies or specialized biotech firms developing PAIS solutions would be indirect competitors.
Market Share Trend
Negligible; the company has not yet commercialized its product for significant market share.
Valuation vs Peers
Not comparable on traditional metrics (P/E, P/S) due to VRAX's lack of revenue and profitability. Valuation would be purely speculative, based on pipeline potential against early-stage biotech peers.
Competitive Advantages
- •Potential proprietary intellectual property around the ViraxImmune™ platform for PAIS, validated by early pilot data (88% specificity, 92% PPV).
- •Early mover advantage in a rapidly emerging and significant market (Long COVID/PAIS diagnostics).
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive VRAX Stock Higher?
Near-Term (0-6 months)
- •Successful completion and positive results from the 300-participant validation study for ViraxImmune™ (est. Q3/Q4 2026) – to validate diagnostic efficacy and specificity for Long COVID/PAIS.
- •Announcement of a strategic partnership or licensing agreement for ViraxImmune™ commercialization (est. late 2026/early 2027) – to provide funding, manufacturing, and market access.
Medium-Term (6-18 months)
- •Regulatory submission and potential approval (e.g., FDA EUA or CE Mark) for ViraxImmune™ in key markets (est. H1 2027) – to enable market entry and revenue generation.
- •Initial commercial sales and revenue generation from ViraxImmune™ in target markets (est. H2 2027) – demonstrating market acceptance and early financial viability.
Long-Term (18+ months)
- •Expansion of ViraxImmune™ platform applications to a broader range of post-acute infection syndromes beyond Long COVID (est. 2028-2029) – significantly expanding the total addressable market.
- •Establishment of Virax as a recognized player in PAIS diagnostics, achieving $20-50M annual revenue run rate by 2029 if commercialization scales effectively.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for VRAX?
- ✓
Watch for the announcement of successful completion and positive data from the 300-participant ViraxImmune™ validation study.
- ✓
Monitor for any news regarding strategic partnerships, licensing agreements, or significant non-dilutive funding rounds.
Bull Case Analysis
Sign up free to see the bull case
Competing with VRAX
See how Virax Biolabs Group Ltd compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Virax Biolabs Group Ltd VRAX | $4.2M | 2.5 | 1321.8 | $4.8M | -188748.8% | -96.5% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Virax Biolabs Group Ltd Makes Money
Virax Biolabs Group Ltd. operates as a pre-revenue biotechnology company focused on the research, development, and potential commercialization of diagnostic technologies, particularly its ViraxImmune™ platform, which aims to identify and manage post-acute infection syndromes (PAIS) like Long COVID. The company currently generates minimal to no revenue, relying on capital raises to fund its R&D efforts. Its future business model is predicated on achieving regulatory approvals and then either directly selling its proprietary diagnostic tests or licensing its technology to larger diagnostic or pharmaceutical companies.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Virax Biolabs Group Ltd (VRAX)?
As of June 8, 2026, Virax Biolabs Group Ltd has a DVR Score of 2.5 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Virax Biolabs Group Ltd?
Virax Biolabs Group Ltd's market capitalization is approximately $4.2M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Virax Biolabs Group Ltd use?
VRAX is the ticker symbol for Virax Biolabs Group Ltd. The company trades on the NCM.
What is the risk level for VRAX stock?
Our analysis rates Virax Biolabs Group Ltd's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of VRAX?
Virax Biolabs Group Ltd currently has a price-to-earnings (P/E) ratio of 1321.8. This is above the market average, suggesting the stock may be priced for high growth expectations.
Is Virax Biolabs Group Ltd's revenue growing?
Virax Biolabs Group Ltd has reported revenue growth of -96.5%. Revenue has been declining, which warrants closer examination.
Is VRAX stock profitable?
Virax Biolabs Group Ltd has a profit margin of -188748.8%. The company is currently unprofitable.
How often is the VRAX DVR analysis updated?
Our AI-powered analysis of Virax Biolabs Group Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 8, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VRAX (Virax Biolabs Group Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.